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ABSTRACT
Introduction In immune- mediated inflammatory diseases, 
there is a lack of -estimates of glucocorticoid dose–
response diabetes risk that consider changes in prescribed 
dose over time and disease activity.
Research design and methods Population- based 
longitudinal analysis of electronic health records from the 
UK Clinical Practice Research Datalink, linked to hospital 
admissions and the mortality registry (1998–2017). 
We included 100 722 adult patients without diabetes 
history, diagnosed with giant cell arteritis or polymyalgia 
rheumatica (n=32 593), inflammatory bowel disease 
(n=29 272), rheumatoid arthritis (n=28 365), vasculitis 
(n=6082), or systemic lupus erythematosus (n=4410). 
We estimated risks and HRs of type 2 diabetes associated 
with time- variant daily and total cumulative prednisolone- 
equivalent glucocorticoid dose using Cox regression 
methods.
Results Average patient age was 58.6 years, 65 469 
(65.0%) were women and 8858 (22.6%) had a body 
mass index (BMI) ≥30 kg/m2. Overall, 8137 (8.1%) people 
developed type 2 diabetes after a median follow- up of 4.9 
years. At 1 year, the cumulative risk of diabetes increased 
from 0.9% during periods of non- use to 5.0% when the 
daily prednisolone- equivalent dose was ≥25.0 mg. We 
found strong dose- dependent associations for all immune- 
mediated diseases, BMI levels and underlying disease 
duration, even after controlling for periods of active 
systemic inflammation. Adjusted HR for a <5.0 mg daily 
dose versus non- use was 1.90, 95% CI 1.44 to 2.50; range 
1.70 for rheumatoid arthritis to 2.93 for inflammatory 
bowel disease.
Conclusions We report dose- dependent risks of type 
2 diabetes associated with glucocorticoid use for six 
common immune- mediated inflammatory diseases. 
These results underline the need for regular diabetic risk 
assessment and testing during glucocorticoid therapy in 
these patients.
INTRODUCTION
Glucocorticoids are often used to treat 
immune- mediated diseases due to their 
potent anti- inflammatory and immu-
nosuppressive effects.1 2 Glucocorticoid 
therapy is the most common cause of drug- 
induced hyperglycemia and drug- induced 
diabetes mellitus.3 4 They might therefore 
have an important contributing role in 
the reportedly increasing global burden of 
diabetes.5–8 Glucocorticoids can unmask 
previously undiagnosed diabetes, trigger new 
(glucocorticoid- induced) diabetes, or aggra-
vate hyperglycemia in patients with a prior 
diagnosis of diabetes mellitus.9 In a random-
ized controlled trial including 41 patients 
with early active rheumatoid arthritis, initia-
tion of prednisolone at 60 or 30 mg/day was 
associated with a 24% increase in incidence 
of type 2 diabetes within 1 week.10 A recent 
Significance of this study
What is already known about this subject?
 ► Diabetes is a known complication of glucocorticoid 
therapy but the magnitude of dose–response for 
common immune- mediated inflammatory diseases 
is uncertain. We report dose- dependent risks of type 
2 diabetes associated with glucocorticoid use for six 
immune- mediated inflammatory diseases, estimat-
ed taking into account changes in prescribed medi-
cation over time.
What are the new findings?
 ► At 1 year of follow- up, the cumulative risk of dia-
betes was 0.9% in periods of non- use, 2.1% when 
the daily prednisolone- equivalent dose was <5 mg, 
and 5.0% when ≥25.0 mg was prescribed. We found 
strong dose- dependent increases in HRs for patients 
with any of the six diseases studied, body mass 
index (BMI), family history of diabetes mellitus or 
disease duration, even after adjusting for periods of 
active systemic inflammation over time.
How might these results change the focus of 
research or clinical practice?
 ► Patients with immune- mediated inflammatory dis-
eases who are prescribed glucocorticoid therapy 
should be screened for diabetes regularly. This rec-
ommendation applies to all patients treated regard-
less of dose, treatment duration, family history of 
diabetes or BMI.
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meta- analysis of 12 studies evaluating the occurrence of 
diabetes in patients receiving systemic glucocorticoids 
reported rates of glucocorticoid- induced diabetes of 
18.6%.11 Although not completely understood, multiple 
pathophysiological mechanisms are responsible for the 
metabolic adverse effects of glucocorticoids, including 
induction of peripheral insulin resistance, hepatic gluco-
neogenesis, and pancreatic islet- cell dysfunction.1 12 
Blood glucose levels of non- diabetic patients sometimes 
normalize after discontinuing glucocorticoids but these 
individuals still have an increased risk of future diabetes 
development in these individuals.13
Accurate estimation of glucocorticoid- induced dose–
response risk of diabetes is hindered by several factors.1 
Patients with a variety of diseases are often treated using 
different glucocorticoid formulations and for differing 
durations. Doses are often modified depending on 
treatment response and disease activity. Furthermore, 
diagnosis of diabetes might be delayed or remain 
under- reported if it is based on the evaluation of fasting 
glucose measurements. The risk of developing diabetes 
depends on various factors including genetic constitu-
tion, age, comorbidity and concomitant medications. 
Most published studies have reported relationships with 
baseline medication use or dose,4 14–16 ignoring changing 
patterns in dose over time and without examining the 
potential role of the severity of the underlying disease 
treated. A cohort study conducted among patients with 
rheumatoid arthritis reported a 25%–30% increased risk 
of diabetes mellitus per each 5 mg increase of current 
glucocorticoids and with longer treatment duration.17 
There is a need for well- conducted cohort studies esti-
mating the glucocorticoid dose–response risk of diabetes 
mellitus among patients with different chronic inflamma-
tory diseases treated with glucocorticoids. Such data will 
facilitate the evaluation of benefits of new glucocorticoid- 
sparing medications.
We conducted a cohort study to quantify the daily and 
cumulative dose- dependent risk of type 2 diabetes asso-
ciated with systemic glucocorticoid use in people with 
six common immune- mediated inflammatory diseases. 
We also examined dose–response associations by type of 
underlying disease, body mass index (BMI) and presence 
or absence of family history of diabetes.
RESEARCH DESIGN AND METHODS
Study setting and data
We used electronic health records from individuals regis-
tered in general practices of the Clinical Practice Research 
Datalink (CPRD) during the period between 1 January 
1998 and 15 March 2017. CPRD gathers longitudinal 
data collected on demographics, health behaviors, labo-
ratory and clinical examinations, diagnoses and complete 
computerized records of all drugs prescribed by general 
practitioners.18 Many studies have provided evidence of 
the validity of diagnostic and prescribing CPRD records 
for research use.18 Patients are largely representative of 
the UK population in terms of sex, age, and ethnicity.18 
Individual records were linked to hospital admissions 
and the mortality registry (online supplementary text 
S1). Hospital records from the Hospital Episode Statistics 
( www. hscic. gov. uk/ hes) gather diagnoses documented 
during hospital admission in all National Health Service 
hospitals in England. The Office for National Statistics 
(https://www. ons. gov. uk/ atoz? query= mortality& size= 
10) provided dates and causes of death.
Study design and follow-up
We identified a cohort of patients aged ≥18 years, 
continuously registered in CPRD practices for 1 year or 
more, who had at least one of six prespecified immune- 
mediated inflammatory diseases (inflammatory bowel 
disease, giant cell arteritis, polymyalgia rheumatica, 
rheumatoid arthritis, systemic lupus erythematosus, and 
vasculitis). To define these diseases, we used the diag-
nostic codes shown in online supplementary table S1. 
The study follow- up started when patients first met all 
the inclusion criteria and ended on the date of last data 
collection, practice deregistration, diagnosis of diabetes 
or death, whichever occurred first. We excluded patients 
with history of diabetes (online supplementary figure 
S1).
Oral glucocorticoid treatment
We identified all the prescriptions of oral, intramuscular 
and intra- articular glucocorticoids that were issued to 
the patients between 1 year prior to study start and the 
end dates. We obtained the daily dose from the recorded 
product name, which included information on product 
strength, directions given and quantity prescribed. We 
estimated the duration of each prescription by dividing 
the amount of tablets prescribed by the daily dose. We 
converted the daily dose into milligrams of prednisolone- 
equivalent dose to account for differences in anti- 
inflammatory potency for different glucocorticoid types 
(online supplementary table S2). We then defined several 
time- variant glucocorticoid exposure variables: ever use 
from 1 year prior to follow- up start (binary); current daily 
use (eg, whether the individual received or not glucocor-
ticoids at a given time point; binary); current daily dose 
per 5 mg/day, with zero value when medication was not 
prescribed (analyzed as continuous and categorical vari-
ables (non- use, >0.0–4.9 mg, 5.0–14.9 mg, 15.0–24.9 mg, 
≥25.0 mg/day)); cumulative dose since 1 year before 
follow- up start per 1000 mg (sum of the total dosages 
prescribed divided by 1000; continuous and categorical 
variables (non- use, >0–959 mg, 960–3054 mg, 3055–7299 
mg, and ≥7300 mg; as previously defined17 19 20)).
Diabetes definition
The primary outcome was the incidence of type 2 diabetes, 
which was defined by the date of the first recorded diag-
nosis (Read21 and International Classification of Diseases 
version 10 codes listed in online supplementary table 
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S3), a recording of glycated hemoglobin (HbA1c) ≥7.0% 
(53 mmol/mol), or a fasting glucose result ≥7.0 mmol/L.
Confounding factors
A priori confounders assessed at baseline were: sex, age, 
type of immune- mediated inflammatory disease (eg, 
vasculitis) and hypertension (diagnosed hypertension, 
≥3 high systolic or diastolic blood pressure measure-
ments within 1 year prior to follow- up start, or ≥2 blood 
pressure- lowering medication prescriptions) in online 
supplementary file 1 . A priori time- variant confounders 
during follow- up were prescribed medication: inhaled, 
nasal, topical and rectal glucocorticoids; and disease- 
modifying antirheumatic drugs (DMARD) and non- 
steroidal anti- inflammatory drugs (NSAID) as markers of 
disease activity. Covariate definitions are shown in online 
supplementary text S1.
Statistical analysis
We imputed missing glucocorticoid daily dose during 
tapering periods using multiple imputation with chained 
equations with generation of five data sets (online 
supplementary text S1). Imputation models included 
patient demographics (sex, age, ethnicity and index of 
multiple deprivation22), underlying immune- mediated 
inflammatory disease, time between follow- up start 
and prescription, type of glucocorticoid (eg, predniso-
lone), and prescribed inhaled, nasal, topical and rectal 
glucocorticoids.
We described baseline patient characteristics using 
summary descriptive statistics and used Kaplan- Meier 
methods to estimate cumulative probabilities of incident 
diabetes. We calculated rates of incidence with 95% CIs 
dividing the number of individuals with incident diabetes 
by the total number of person- years of follow- up.
We studied the effect of time- variant glucocorticoid 
exposure on diabetes using Cox proportional hazards 
models adjusted for the a priori confounders. We 
included the practice identifier as a random intercept to 
account for clustering effect, and no interaction terms. 
We assessed the proportional hazards assumption using 
Schoenfeld residual tests. We combined estimates and 
95% CIs from each imputed data set using Rubin’s rules. 
We considered significance as p<0.05 and used two- sided 
tests. We used Stata V.15 (StataCorp, College Station, 
USA) for data management and R V.3.3.1 (http:// cran. 
r- project. org/) for the analysis.
Secondary analyses included estimations by sex, BMI 
group (18.5–24.9, 25.0–29.9, ≥30.0 kg/m2), diabetes 
family history status, type of immune- mediated inflam-
matory disease, and according to duration of the under-
lying inflammatory disease at follow- up start (newly 
diagnosed/incident, within 2 years and over 2 years since 
diagnosis).
In sensitivity analyses, we further adjusted the esti-
mates for periods of active systemic inflammation, which 
was defined based on prescribed glucocorticoid dose 
(increase in prednisolone- equivalent dose by >5 or 10 mg 
that sustained for over 3 weeks) and, except for patients 
who only had vasculitis or systemic lupus erythematosus, 
also on erythrocyte sedimentation rate and C- reactive 
protein values (≥30 mm/hour and ≥10 mg/L, respec-
tively) (online supplementary text S1). We included this 
variable as a time- variant covariate to take into account 
changes in systemic inflammation activity over time.
The study funders had no role in the study design, 
data collection, analysis or interpretation, in the writing 




We included 100 722 patients from 389 general practices; 
32 593 (32.4%) with polymyalgia rheumatica or giant 
cell arteritis, 29 272 (29.1%) with inflammatory bowel 
disease, 28 365 (28.2%) with rheumatoid arthritis, 4410 
(4.4%) with systemic lupus erythematosus, and 6082 
(6.0%) with vasculitis (table 1). Patient mean age ranged 
from 54.5 years (SD 17.3) for inflammatory bowel disease 
to 72.9 (SD 10.8) for polymyalgia rheumatica or giant cell 
arteritis. Sixty- five percent (n=65 469) were women, 7996 
(7.9%) had family history of diabetes and 8858 (22.6%) 
had a BMI ≥30 kg/m2. At follow- up start, the median 
duration since immune- mediated disease diagnosis was 
8.0 years (IQR=4.0–13.0) and the most common comor-
bidities diagnosed were hypertension (29.3%), cardiovas-
cular disease (19.1%), and asthma (15.1%).
In the year prior to follow- up start, 17 240 (17.1%) 
patients received oral, intramuscular or intra- articular 
glucocorticoids, 10 270 (10.7%) inhaled or nasal gluco-
corticoids and 46 680 (48.4%) NSAIDs. During follow- up 
19 723 (20.5%; range 3.8% for polymyalgia or giant cell 
arteritis to 46.7% for rheumatoid arthritis) received 
DMARDs.
Incidence and cumulative risk of type 2 diabetes
Diabetes mellitus was diagnosed in 8137 (8.1%) patients 
during 668 601 person- years of follow- up (median time 
per patient was 4.9, IQR 2.1–6.0 years; online supple-
mentary table S4); 4727 events occurred during periods 
without glucocorticoid therapy. The incidence rate of 
diabetes was 12.2 per 1000 person- years (95% CI 11.9 to 
12.4). This incidence rate increased from 9.2 (95% CI 
9.0 to 9.5) per 1000 person- years during periods without 
prescribed glucocorticoids (unexposed periods) to 20.4 
(95% CI 18.5 to 22.5) per 1000 person- years during 
periods with ≥25 mg daily dose; and from 12.6 (95% CI 
12.1 to 13.1) per 1000 person- years during unexposed 
periods to 10.5 (95% CI 10.0 to 11.0) per 1000 person- 
years during periods when the cumulative dose was 
≥7300 mg.
The cumulative risk of diabetes at 1 year increased 
from 0.9% (95% CI 0.8% to 1.0%) for periods without 
prescribed glucocorticoids, through 2.1% (95% CI 1.9% 
to 2.4%) for <5 mg, to 5.0% (95% CI 4.0% to 6.0%) for 
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n=100 722 n=32 593 n=29 272 n=28 365 n=4410 n=6082
Follow- up time in years, 
median (IQR)
4.9 (2.1–6.0) 4.4 (1.9–5.4) 5.1 (2.1–6.4) 5.3 (2.3–6.4) 5.3 (2.1–6.4) 4.3 (1.8–5.4)
Total 668 601 204 172 199 180 198 199 30 173 36 986
Since first recorded immune- 
mediated disease diagnosis
8.0 (4.0, 13.0) 6.0 (3.0, 10.0) 9.0 (4.0, 16.0) 9.0 (4.0, 15.0) 9.0 (4.0, 15.0) 6.0 (3.0, 11.0)
Sociodemographic information
  Age in years, mean (SD) 58.6 (18.7) 72.9 (10.8) 45.4 (17.3) 58.9 (15.5) 47.9 (15.6) 52.8 (19.1)
  Women, n (%) 65 469 (65.0) 22 699 (69.6) 15 376 (52.5) 20 232 (71.3) 3709 (84.1) 3453 (56.8)
Ethnicity, n (%)
  White 88 040 (87.4) 29 030 (89.1) 26 019 (88.9) 24 475 (86.3) 3369 (76.4) 5147 (84.6)
  Asian 2595 (2.6) 342 (1.0) 986 (3.4) 788 (2.8) 283 (6.4) 196 (3.2)
  Black 1012 (1.0) 124 (0.4) 240 (0.8) 332 (1.2) 249 (5.6) 67 (1.1)
  Other 1138 (1.1) 193 (0.6) 434 (1.5) 310 (1.1) 133 (3.0) 68 (1.1)
Index of multiple deprivation, n (%)
  1st (least deprived) 18 061 (17.9) 6357 (19.5) 5349 (18.3) 4483 (15.8) 725 (16.4) 1147 (18.9)
  5th (most deprived) 16 513 (16.4) 4195 (12.9) 4869 (16.6) 5558 (19.6) 885 (20.1) 1006 (16.5)
Biomarkers, mean (SD)
  Body mass index (kg/m2) 26.5 (5.6) 26.9 (5.3) 25.5 (5.4) 27.1 (5.9) 26.2 (5.6) 27.4 (6.3)
  C- reactive protein (mg/L) 25.3 (38.9) 33.6 (43.4) 19.3 (38.5) 20.2 (31.0) 7.6 (13.0) 20.7 (39.3)
  Erythrocyte sedimentation 
rate (mm/hour)
32.1 (27.4) 40.1 (29.1) 20.3 (20.9) 28.5 (24.7) 22.3 (22.5) 22.5 (24.4)
  Total cholesterol (mmol/L) 5.1 (1.2) 5.1 (1.2) 5.0 (1.1) 5.2 (1.1) 5.1 (1.2) 5.1 (1.2)
  LDL cholesterol (mmol/L) 3.0 (1.0) 3.0 (1.0) 3.0 (1.0) 3.1 (1.0) 3.2 (1.0) 3.0 (1.0)
  Systolic blood pressure 
(mm Hg)
134 (19.4) 140 (18.4) 127 (17.9) 134 (19.1) 127 (18.6) 133 (19.2)
  Diastolic blood pressure 
(mm Hg)
78 (10.3) 78 (10.1) 76 (10.2) 79 (10.4) 77 (10.5) 78 (10.6)
Family history of diabetes 7996 (7.9) 1887 (5.8) 2691 (9.2) 2399 (8.5) 484 (11.0) 535 (8.8)
Smoking status, n (%)
  Non- smoker 37 324 (37.1) 14 188 (43.5) 9791 (33.4) 9674 (34.1) 1331 (30.2) 2340 (38.5)
  Ex- smoker 14 473 (14.4) 6432 (19.7) 3461 (11.8) 3493 (12.3) 305 (6.9) 782 (12.9)
  Current smoker 24 099 (23.9) 6577 (20.2) 6981 (23.8) 8003 (28.2) 1119 (25.4) 1419 (23.3)
Comorbidities, n (%)
  Hypertension 29 506 (29.3) 15 137 (46.4) 4046 (13.8) 7560 (26.7) 948 (21.5) 1815 (29.8)
  Cardiovascular disease 19 198 (19.1) 9628 (29.5) 2795 (9.5) 4827 (17.0) 668 (15.1) 1280 (21.0)
  Asthma 15 226 (15.1) 4909 (15.1) 4574 (15.6) 4104 (14.5) 569 (12.9) 1070 (17.6)
  Chronic obstructive 
inflammatory disease
4723 (4.7) 2215 (6.8) 745 (2.5) 1465 (5.2) 83 (1.9) 215 (3.5)
  Cancer 6581 (6.5) 3169 (9.7) 1180 (4.0) 1626 (5.7) 192 (4.4) 414 (6.8)
  Renal disease 2887 (2.9) 1548 (4.7) 366 (1.3) 652 (2.3) 92 (2.1) 229 (3.8)
Prescribed medication in last year, n (%)     
  Blood pressure- lowering 
medication
33 198 (33.0) 16 807 (51.6) 4789 (16.4) 8565 (30.2) 1069 (24.2) 1968 (32.4)
  Statins 13 371 (13.3) 7247 (22.2) 1771 (6.1) 3098 (10.9) 430 (9.8) 825 (13.6)
  Oral, intramuscular or intra- 
articular glucocorticoids
17 240 (17.1) 6737 (20.7) 4318 (14.8) 4767 (16.8) 767 (17.4) 651 (10.7)
Continued
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≥25.0 mg daily dose (online supplementary table S5). 
We generally found stronger dose–response estimates in 
men than in women, especially for systemic lupus erythe-
matosus and vasculitis (online supplementary tables S6 
and S7).
Association between glucocorticoid dose and type 2 diabetes
We observed strong dose–response effects for both daily 
and cumulative dose for patients with and without family 
history of diabetes, and for each immune- mediated 
inflammatory disease (figure 1 and table 2). The adjusted 
HR for periods with a daily dose >0–4.9 mg was 1.90 
(95% CI 1.73 to 2.09); range 1.28 for vasculitis to 2.09 
for inflammatory bowel disease. The overall increase in 
HR per 5 mg daily dose was 1.01 (95% CI 1.00 to 1.01), 
ranging from 1.02 (95% CI 1.01 to 1.04) for polymyalgia 
rheumatica or giant cell arteritis to 1.23 (95% CI 1.17 
to 1.30) for systemic lupus erythematosus. This estimate 
was slightly higher for patients with a family history of 
diabetes compared with those without (1.96 (95% CI 
1.42 to 2.70) vs 1.90 (95% CI 1.72 to 2.10)). Adjusted HRs 
were higher for daily doses <15 mg during the earlier 
periods following the underlying inflammatory disease 
diagnosis, compared with later periods (eg, 2.09 (95% CI 
1.86 to 2.34) within the year of diagnosis, 1.90 (95% CI 
1.44 to 2.50) within the second year of diagnosis and 1.51 
(95% CI 1.24 to 1.84) after 2 years of diagnosis; online 
supplementary tables S8–S10). However, estimates were 
generally higher for daily doses ≥15 mg in longer periods 
after diagnosis, compared with earlier periods.
The percentage of patients with baseline BMI 18.5–24.9 
kg/m2, 25.0–29.9 kg/m2 and ≥30 kg/m2 who developed 
type 2 diabetes was 4.5%, 7.9% and 14.0%, respectively. 
Dose–response effects were similar regardless of BMI but, 
among patients with normal weight, lower estimates were 
observed during periods with a daily dose >0–4.9 mg and 
higher estimates during periods with higher daily doses, 
compared with patients with higher BMI (figure 2; online 
supplementary figures S2–S6). Further, adjustment for 
periods of active systemic inflammation during follow- up 
generally decreased the size of the dose–response 
Figure 1 Associations between time- variant prescribed oral glucocorticoids and incident type 2 diabetes for patients with any 
of the six immune- mediated inflammatory diseases included. HRs from Cox proportional imputed models adjusted for baseline 
age, sex, hypertension, prescribed non- oral glucocorticoids and blood pressure- lowering medication, and immune- mediated 
inflammatory disease type; and time- variant use of disease- modifying antirheumatic drugs and non- steroidal anti- inflammatory 














n=100 722 n=32 593 n=29 272 n=28 365 n=4410 n=6082
  Inhaled or nasal 
glucocorticoids
10 270 (10.7) 3875 (12.6) 2421 (8.6) 2973 (10.9) 306 (7.2) 694 (12.0)
  Rectal glucocorticoids 6159 (6.4) 691 (2.2) 4726 (16.7) 543 (2.0) 72 (1.7) 127 (2.2)
  Topical glucocorticoids 2464 (2.6) 827 (2.7) 666 (2.4) 611 (2.2) 149 (3.5) 210 (3.6)
  Non- steroidal anti- 
inflammatory drugs
46 680 (48.4) 18 024 (58.4) 5953 (21.1) 19 219 (70.5) 1558 (36.9) 1923 (33.1)
DMARDs ever during follow- up 19 723 (20.5) 1171 (3.8) 4131 (14.6) 12 726 (46.7) 1364 (32.3) 329 (5.7)
Percentage of patients with missing ethnicity, body mass index, C- reactive protein, erythrocyte sedimentation rate, total cholesterol, LDL 
cholesterol, systolic blood pressure, and smoking status was 7.9%, 61.0%, 68.8%, 57.9%, 73.6%, 83.9%, 47.7%, 36.6%, and 24.6%, respectively.
DMARD, disease- modifying antirheumatic drug; LDL, low- density lipoprotein.
Table 1 Continued
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estimates, but associations remained statistically signifi-
cant (online supplementary tables S11 and S12).
CONCLUSIONS
In this longitudinal study of 100 722 adults with six 
immune- mediated inflammatory diseases, we quantified 
glucocorticoid dose- dependent risks of type 2 diabetes, 
taking into account changes in prescribed prednisolone- 
equivalent dose over time. At 1 year of follow- up, the 
cumulative risk of diabetes was 0.9% during periods of 
non- use, 2.1% when the daily dose was <5 mg, and 5.0% 
when ≥25.0 mg of prednisolone- equivalent daily dose 
Table 2 Associations between time- variant prednisolone- equivalent glucocorticoid dose and incident type 2 diabetes by 
immune- mediated inflammatory disease
Adjusted HRs with 95% CI
Polymyalgia 






Events (n) 3236 1831 2303 276 491
Ever use (ref non- use since 1 
year before follow- up start)
1.33 (1.18 to 1.51) 1.32 (1.19 to 1.45) 1.41 (1.29 to 1.54) 1.53 (1.18 to 1.99) 1.30 (1.08 to 1.57)
Current use (ref non- use) 2.32 (2.15 to 2.51) 2.86 (2.55 to 3.20) 2.01 (1.84 to 2.20) 2.71 (2.05 to 3.57) 2.20 (1.79 to 2.71)
Current daily dose per 
5 mg/day
1.02 (1.01 to 1.04) 1.05 (1.04 to 1.06) 1.03 (1.02 to 1.04) 1.23 (1.17 to 1.30) 1.20 (1.15 to 1.26)
Current daily dose in mg 
(ref non- use)
1.00 1.00 1.00 1.00 1.00
  >0–4.9 2.00 (1.79 to 2.23) 2.09 (1.53 to 2.88) 1.66 (1.37 to 2.02) 1.72 (0.93 to 3.19) 1.28 (0.52 to 3.12)
  5.0–14.9 2.29 (2.07 to 2.53) 2.34 (1.93 to 2.84) 1.90 (1.71 to 2.12) 2.67 (1.94 to 3.68) 2.14 (1.57 to 2.90)
  15.0–24.9 3.14 (2.64 to 3.74) 4.20 (2.90 to 6.07) 3.07 (2.28 to 4.14) 3.00 (1.05 to 8.59) 3.04 (1.89 to 4.87)
  ≥25 3.88 (3.20 to 4.71) 5.05 (4.09 to 6.24) 4.00 (3.08 to 5.21) 6.63 (3.55 to 12.38) 3.66 (2.21 to 6.06)
Cumulative dose 
per 1000 mg
1.03 (1.02 to 1.03) 1.01 (1.00 to 1.01) 1.02 (1.01 to 1.02) 1.03 (1.01 to 1.04) 1.01 (1.00 to 1.02)
Cumulative dose in mg 
(ref non- use)
1.00 1.00 1.00 1.00 1.00
  1.0–959.9 1.12 (0.96 to 1.31) 1.25 (1.09 to 1.42) 1.17 (1.04 to 1.32) 1.20 (0.83 to 1.75) 1.24 (0.97 to 1.59)
  960.0–3054.9 1.27 (1.11 to 1.46) 1.27 (1.10 to 1.46) 1.44 (1.25 to 1.65) 1.01 (0.61 to 1.69) 1.32 (0.95 to 1.85)
  3055.0–7299.9 1.24 (1.08 to 1.42) 1.37 (1.17 to 1.60) 1.58 (1.38 to 1.82) 2.40 (1.64 to 3.52) 1.26 (0.92 to 1.74)
  ≥7300.0 1.86 (1.62 to 2.14) 1.55 (1.31 to 1.83) 1.61 (1.42 to 1.81) 1.87 (1.30 to 2.69) 1.44 (1.07 to 1.95)
HRs from Cox proportional imputed models adjusted for baseline age, sex, hypertension, prescribed non- oral glucocorticoids and blood pressure- 
lowering medication, and underlying inflammatory disease type; and time- variant use of disease- modifying antirheumatic drugs and non- steroidal 
anti- inflammatory drugs; the general practice identifier was included as a random intercept to account for clustering effect.
Figure 2 HRs with 95% CIs for the association between time- variant oral glucocorticoid dose and type 2 diabetes for 
patients with any of the six immune- mediated inflammatory diseases, stratified by BMI group. HRs from Cox proportional 
imputed models adjusted for baseline age, sex, hypertension, prescribed non- oral glucocorticoids and blood pressure- lowering 
medication, and immune- mediated inflammatory disease type; and time- variant use of disease- modifying antirheumatic drugs 
and non- steroidal anti- inflammatory drugs; the general practice identifier was included as a random intercept to account for 
clustering effect. BMI, body mass index.
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was prescribed. We observed strong dose- dependent 
increases in HRs for patients with all underlying immune- 
mediated diseases, irrespective of BMI, family history of 
diabetes mellitus or disease duration, even after adjusting 
for systemic inflammation activity over time.
Our findings are consistent with those from previous 
studies. Results from a recent meta- analysis including 12 
studies evaluating the risk of hyperglycemia in patients 
treated with systemic glucocorticoids showed rates of 
glucocorticoid- induced hyperglycemia and diabetes 
of 32.3% and 18.6%, respectively.11 In a case–control 
study investigating the risk of diabetes requiring antidi-
abetic treatment, the ORs associated with <10 and >25 
mg prednisolone- equivalent dose were 1.36 (95% CI 
1.10 to 1.69) and 5.82 (95% CI 2.47 to 12.35), respec-
tively.4 Furthermore, a longitudinal study of patients 
with rheumatoid arthritis found a 25%–30% increase 
in risk of diabetes associated with each 5 mg increase 
in current prednisolone- equivalent dose; only medica-
tion taken in the previous 6 months was associated with 
current diabetes risk.17 However, in that study no statisti-
cally significant difference was found for the increase in 
diabetes risk for a dose <5 mg, compared with non- use.
The dose- dependent increased risk of type 2 diabetes 
with glucocorticoid therapy highlights the need for 
physicians to educate patients prescribed glucocorti-
coids for immune- mediated inflammatory diseases on 
the risks of glucocorticoid- induced hyperglycemia and 
the action patients should take if possible symptoms 
of hyperglycemia occur. Physicians should also ensure 
regular evaluation of diabetes status, irrespective of the 
dose of glucocorticoid prescribed. These results also 
reinforce the principle that glucocorticoids should be 
prescribed at the lowest dose and for the shortest dura-
tion needed to control disease activity, and that appro-
priate glucocorticoid- sparing therapies are important to 
consider where such option exists.
By analyzing a cohort of all people diagnosed with six 
immune- mediated inflammatory diseases, irrespective 
of disease duration or activity level, we increased the 
generalizability of our findings. To prevent the introduc-
tion of time- related bias, the beginning of follow- up was 
unrelated to the start or use of glucocorticoid treatment 
and we used time- variant exposure and confounding 
medication variables. We improved the ascertainment 
of the outcome through analysis of linked electronic 
medical records from three data sources (primary care, 
hospital admissions and the death registry). We defined 
the outcome using diagnostic codes previously used 
for research23 and clinically reviewed by the authors, as 
well as HbA1c and fasting glucose measurements. Some 
patients might however have being missed because HbA1c 
testing reflects glycemia over the previous 2–3 months12 
and because glucocorticoids can increase postpran-
dial glucose levels without necessarily affecting fasting 
glucose measurements.1 All medication prescribed in 
primary care, where the majority of care occurs for 
patients with these six immune- mediated diseases, is 
contemporaneously recorded. We extracted the daily 
dose of oral, intra- articular and parenterally adminis-
tered glucocorticoids and the duration of use from the 
recorded instructions on how to take the medication 
directions for each prescription. When these were unde-
fined (eg, written ‘as directed’ during dose tapering) we 
used information on the longitudinal doses prescribed to 
patients to impute the dose taken. Data on drug adher-
ence or on medication prescribed in hospitals were not 
available. This is likely to have led to dose underestima-
tion during periods of outpatient or inpatient manage-
ment and may have led to dose overestimation during 
periods of drug tapering. This misclassification is likely 
to have underestimated dose–response effects. Although 
there is no clear evidence that diabetes risk is affected 
by the level of systemic inflammation, we investigated 
its potential effect and the possibility of ascertainment 
bias through further adjustment for both periods of 
active systemic inflammation and prescribed medi-
cation (DMARDs and NSAIDs) during follow- up and 
conducting analyses in patient subgroups defined by the 
time since immune- mediated disease diagnosis. Similar 
dose–response patterns were obtained. We adjusted esti-
mates of risk for basic sociodemographic factors, medi-
cation use and type of immune- mediated inflammatory 
disease. Dose–response estimates were similar in groups 
defined according to recorded family history of diabetes 
status or baseline BMI and after further adjusting for 
changing periods of active systemic inflammation.
In conclusion, we reported improved estimates of 
glucocorticoid- induced diabetes for people with six 
immune- mediated inflammatory diseases. Our results 
underscore the need to educate patients treated with 
glucocorticoids on recognition of typical symptoms and 
to provide adequate follow- up to ensure early identifica-
tion and management of diabetes. This recommendation 
applies to all patients treated regardless of dose, treat-
ment duration, family history of diabetes or BMI.
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